Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $615 Billion
  • Q3 2024

Adar1 Capital Management, LLC has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $615 Billion distributed in 278 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Cytokinetics Inc with a value of $48.1B, Protagonist Therapeutics, Inc with a value of $44.2B, Bridge Bio Pharma, Inc. with a value of $36.9B, Ea Series Trust with a value of $35.2B, and Roivant Sciences Ltd. with a value of $34.9B.

Examining the 13F form we can see an increase of $85.2B in the current position value, from $530B to 615B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $615 Billion
Healthcare: $433 Billion
ETFs: $6.5 Billion
Communication Services: $3.51 Billion
Utilities: $1.26 Billion
Technology: $995 Million
Industrials: $511 Million
Real Estate: $132 Million
Basic Materials: $121 Million
Other: $293 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$4.57B
$48.1 Billion 7.82% of portfolio
911,182
Q3 2024 Added 6.71%
$1.94B
$44.2 Billion 7.18% of portfolio
981,295
Q3 2024 Reduced 38.82%
$4.21B
$36.9 Billion 6.0% of portfolio
1,448,470
Q3 2024 Added 14.54%
Ea Series Trust
-
$35.2 Billion 5.73% of portfolio
-
Q3 2024 Reduced 7.99%
$8.45B
$34.9 Billion 5.68% of portfolio
3,025,450
Q3 2024 Reduced 27.1%
$3.55B
$32.3 Billion 5.25% of portfolio
1,131,707
Q3 2024 Added 137.48%
$11.1B
$31 Billion 5.05% of portfolio
1,096,666
Q3 2024 Reduced 7.17%
$433M
$25.8 Billion 4.2% of portfolio
445,068
Q3 2024 Reduced 18.92%
$7.83B
$24.1 Billion 3.92% of portfolio
161,402
Q3 2024 Added 214.85%
Zura Bio LTD
-
$15.3 Billion 2.49% of portfolio
-
Q3 2024 New
$2.67B
$12.9 Billion 2.09% of portfolio
532,454
Q3 2024 Added 2,320.25%
Kiniksa Pharmaceuticals Intl
-
$10.9 Billion 1.77% of portfolio
-
Q3 2024 Added 282.01%
Aa Mission Acquisition Corp
-
$10.1 Billion 1.65% of portfolio
-
Q3 2024 New
Mineralys Therapeutics Inc
-
$8.83 Billion 1.44% of portfolio
-
Q3 2024 Added 2,775.51%
$478M
$8.04 Billion 1.31% of portfolio
2,089,321
Q3 2024 Reduced 36.48%
Solid Biosciences Inc
-
$7.98 Billion 1.3% of portfolio
-
Q3 2024 Reduced 19.35%
$182M
$7.62 Billion 1.24% of portfolio
1,571,705
Q3 2024 Reduced 23.85%
Perceptive Cap Solutions Cor
-
$7.52 Billion 1.22% of portfolio
-
Q2 2024 New
$1.48B
$6.88 Billion 1.12% of portfolio
342,262
Q3 2024 New
$731M
$6.74 Billion 1.1% of portfolio
350,206
Q3 2024 New
Anaptysbio Inc
-
$6.46 Billion 1.05% of portfolio
-
Q3 2024 Added 23.7%
Abivax Sa
-
$6.01 Billion 0.98% of portfolio
-
Q3 2024 Added 1,831.9%
$340M
$5.97 Billion 0.97% of portfolio
569,008
Q3 2024 Added 20,974.37%
$21.6B
$5.74 Billion 0.93% of portfolio
29,625
Q3 2024 New
-
$5.66 Billion 0.92% of portfolio
-
Q3 2024 Added 87.68%
Cg Oncology Inc
-
$5.4 Billion 0.88% of portfolio
-
Q3 2024 Added 1,013.65%
$2.9B
$4.52 Billion 0.73% of portfolio
88,425
Q3 2024 Added 18.14%
Helix Acquisition Corp Ii
-
$4.22 Billion 0.69% of portfolio
-
Q2 2024 Added 0.16%
$264M
$3.85 Billion 0.63% of portfolio
376,737
Q3 2024 Added 527.9%
Tectonic Therapeutic Inc
-
$3.85 Billion 0.63% of portfolio
-
Q3 2024 Reduced 64.37%
$277M
$3.84 Billion 0.62% of portfolio
1,005,750
Q3 2024 Reduced 40.79%
$9.02B
$3.51 Billion 0.57% of portfolio
122,807
Q3 2024 Added 1,056.92%
Apogee Therapeutics Inc
-
$3.36 Billion 0.55% of portfolio
-
Q3 2024 Added 39.9%
Dianthus Therapeutics Inc
-
$3.25 Billion 0.53% of portfolio
-
Q3 2024 New
$374M
$3.15 Billion 0.51% of portfolio
742,634
Q3 2024 Added 11.91%
$2.86B
$2.97 Billion 0.48% of portfolio
101,826
Q3 2024 Added 167.96%
Acasti Pharma Inc
-
$2.88 Billion 0.47% of portfolio
-
Q3 2024 New
Q32 Bio Inc
-
$2.87 Billion 0.47% of portfolio
-
Q3 2024 Reduced 58.95%
$683M
$2.76 Billion 0.45% of portfolio
246,128
Q3 2024 Added 2,361.28%
$1.25B
$2.53 Billion 0.41% of portfolio
557,159
Q3 2024 Added 519.07%
Pieris Pharmaceuticals Inc
-
$2.4 Billion 0.39% of portfolio
-
Q3 2024 New
$982M
$2.39 Billion 0.39% of portfolio
319,185
Q3 2024 Added 190.17%
Cellectar Biosciences Inc
-
$2.19 Billion 0.36% of portfolio
-
Q3 2024 Added 49.86%
$4.9B
$2.08 Billion 0.34% of portfolio
74,431
Q3 2024 Reduced 62.14%
$3.97B
$2.01 Billion 0.33% of portfolio
44,351
Q3 2024 New
$0
$2 Billion 0.33% of portfolio
21,786
Q3 2024 Reduced 32.97%
$150M
$2 Billion 0.32% of portfolio
428,802
Q3 2024 Added 119.55%
$25.1B
$1.95 Billion 0.32% of portfolio
108,171
Q3 2024 Added 4.9%
Kala Bio Inc
-
$1.74 Billion 0.28% of portfolio
-
Q2 2024 New

Summary

  • Portfolio
  • No. of Stocks 278
  • Current Value $615 Billion
  • Prior Value $530 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 89 stocks
  • Additional Purchases 75 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 70 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email